Biogen
BIIB
Market cap $16.8B

115.44 USD

-3.17

2.67%

Updated Apr 21, 2:15 PM EDT

1 day

-2.67%

5 days

-0.92%

1 month

-18.07%

3 months

-18.12%

6 months

-37.48%

Year to date

-23.04%

1 year

-40.53%

5 years

-64.91%

10 years

-72.65%

About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Employees: 7,570

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,419 funds

0

Analysts bullish %

of 11 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

3.13% more ownership

Funds ownership: 86.97% [Q3] → 90.1% (+3.13%) [Q4]

7% less repeat investments, than reductions

Existing positions increased: 291 | Existing positions reduced: 313

5% less funds holding

Funds holding: 896 [Q3] → 851 (-45) [Q4]

13% less call options, than puts

Call options by funds: $308M | Put options by funds: $356M

18% less capital invested

Capital invested by funds: $24.5B [Q3] → $20.1B (-$4.4B) [Q4]

18% less first-time investments, than exits

New positions opened: 128 | Existing positions closed: 157

50% less funds holding in top 10

Funds holding in top 10: 8 [Q3] → 4 (-4) [Q4]

See Fund Rankings

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$135

17%

upside

Avg. target

$193

67%

upside

High target

$265

130%

upside

11 analyst ratings

6 positive

55%

5 neutral

45%

0 negative

0%

Morgan Stanley Matthew Harrison 38% 1-year accuracy 9 / 24 met price target	32%upside $152	Equal-Weight Maintained	9 Apr 2025
Piper Sandler Christopher Raymond 25% 1-year accuracy 7 / 28 met price target	17%upside $135	Neutral Reiterated	18 Feb 2025
Scotiabank George Farmer 19% 1-year accuracy 4 / 21 met price target	94%upside $224	Sector Outperform Maintained	13 Feb 2025
BMO Capital Evan Seigerman 62% 1-year accuracy 8 / 13 met price target	20%upside $139	Market Perform Maintained	13 Feb 2025
Goldman Sachs Salveen Richter 11% 1-year accuracy 2 / 18 met price target	112%upside $245	Buy Maintained	13 Feb 2025

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about BIIB published over the past 30 days

Zacks Investment Research

Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi

Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's disease in the region.

Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) who are apolipoprotein E ε4 (ApoE ε4 * ) non-carriers or heterozygotes with confirmed amyloid pathology

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union

EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat mild cognitive impairment in the early stages of Alzheimer's disease.

EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease

Investors Business Daily

Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.

Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might "go wild" on biotech stocks.

Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.

Zacks Investment Research

Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?

Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?

Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag

Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline, despite the market's current undervaluation. Sage's Zuranolone shows strong market traction in PPD, with significant insurance coverage and increasing prescriptions, indicating future growth potential.

Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag

Zacks Investment Research

BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag

The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease candidate.

BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag

Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs.

Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease

Proactive Investors

Biopharma firms with foreign exposure face disruption as Trump's tariffs loom

The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.

Biopharma firms with foreign exposure face disruption as Trump's tariffs loom

Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.

Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-8.32% say there is a smart way to play the sector.

Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.

See News Rankings

Charts implemented using Lightweight Charts™